Back to Journals » Cancer Management and Research » Volume 5

The claudin family of proteins in human malignancy: a clinical perspective

Authors Ding L , Lu Z, Lu Q, Chen Y

Received 22 July 2013

Accepted for publication 7 October 2013

Published 8 November 2013 Volume 2013:5 Pages 367—375

DOI https://doi.org/10.2147/CMAR.S38294

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 6



Lei Ding,1,2 Zhe Lu,2,4 Qun Lu,2,3 Yan-Hua Chen2,3

1Department of Oncology, Beijing Shijitan Hospital, Capital Medical University, Beijing, People's Republic of China; 2Department of Anatomy and Cell Biology, 3Leo W. Jenkins Cancer Center, Brody School of Medicine, East Carolina University, Greenville, NC, USA; 4Department of Basic Medicine, Hangzhou Normal University, Hangzhou, People's Republic of China

Abstract: Tight junctions, or zonula occludens, are the most apical component of the junctional complex and provide one form of cell–cell adhesion in epithelial and endothelial cells. Nearly 90% of malignant tumors are derived from the epithelium. Loss of cell–cell adhesion is one of the steps in the progression of cancer to metastasis. At least three main tight junction family proteins have been discovered: occludin, claudin, and junctional adhesion molecule (JAM). Claudins are the most important structural and functional components of tight junction integral membrane proteins, with at least 24 members in mammals. They are crucial for the paracellular flux of ions and small molecules. Overexpression or downregulation of claudins is frequently observed in epithelial-derived cancers. However, molecular mechanisms by which claudins affect tumorigenesis remain largely unknown. As the pivotal proteins in epithelial cells, altered expression and distribution of different claudins have been reported in a wide variety of human malignancies, including pancreatic, colonic, lung, ovarian, thyroid, prostate, esophageal, and breast cancers. In this review, we will give the readers an overall picture of the changes in claudin expression observed in various cancers and their mechanisms of regulation. Downregulation of claudins contributes to epithelial transformation by increasing the paracellular permeability of nutrients and growth factors to cancerous cells. In the cases of upregulation of claudin expression, the barrier function of the cancerous epithelia changes, as they often display a disorganized arrangement of tight junction strands with increased permeability to paracellular markers. Finally, we will summarize the literature suggesting that claudins may become useful biomarkers for cancer detection and diagnosis as well as possible therapeutic targets for cancer treatment.

Keywords: tight junctions, claudins, human cancers

Creative Commons License © 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.